Loading

An Eye on I&I: Innovations Fueling Growth

June 19, 2025
Breakout Session
Next Generation Biotherapeutics
The global immunology market is projected to nearly double by 2032, expanding from $250 billion in 2023. Immunology and Inflammation (I&I) has now emerged as a top investment priority in biopharma, surpassing oncology in growth. This surge is fueled by groundbreaking innovations from both biotech and pharma. In this panel, leaders from four pioneering biotech and pharma companies, along with a leading venture capitalist, will explore the key scientific advancements, emerging platforms, and breakthrough technologies driving I&I growth. They will also discuss which innovations are attracting major investments and strategic industry partnerships, shaping the future of this rapidly evolving field.
Moderator
Allison deAngelis
Biotech Startups and Venture Capital Reporter Biotech Startups and Venture Capital Reporter Biotech Startups and Venture Capital Reporter
STAT News
Speakers
Kari Brown, MD
Chief Medical Officer
Revolo Biotherapeutics
Judy Chou, PhD
President and CEO
AltruBio
Frank Nestle, MD
Partner and CEO of 3DC
Deerfield Management
Dan Passeri, MSc, JD
Chief Executive Officer
Cue Biopharma
Jose Terencio, PhD
Senior Vice President, Discovery
Grifols

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS